China-developed Innovative Drug "Linaprazan Glurate Capsules" Launches Nationwide with First Batch Shipment, Offering New Option for Patients with Reflux Esophagitis

On January 5, 2026, the first batch of Linaprazan Glurate Capsules (trade name: Xinlian®), a Class 1 innovative drug independently developed by Sinorda Biotechnology , was shipped for nationwide launch. This milestone marks the official clinical application of the world’s first Potassium-Competitive Acid Blocker (P-CAB) with an ester bond structure, bringing a brand-new treatment option to domestic patients suffering from reflux esophagitis.
 

As a next-generation P-CAB, Linaprazan Glurate Capsules features an innovative ester bond structure designed to enhance gastrointestinal absorption efficiency, delivering rapid, stable and precise acid-suppressive effects. The drug was included in the National Basic Medical Insurance Catalogue in December 2025, a move that will significantly reduce patients’ medication costs, improve drug accessibility and enable more patients to benefit from this innovative therapy. Beyond its approved indication for reflux esophagitis, Sinorda Biotechnology is actively advancing Phase III clinical trials of the drug for additional indications including duodenal ulcer and Helicobacter pylori eradication, with the aim of providing a more comprehensive treatment solution for digestive system disorders in the future.
 

The first batch of the shipped drug will be rapidly distributed across the country via the commercial network of its partner, Huadong Medicine. Sinorda Biotechnology remains committed to addressing unmet clinical needs of patients through genuine technological innovation.